Clinical Trial Details
— Status: Terminated
Administrative data
NCT number |
NCT04807387 |
Other study ID # |
H-45549 |
Secondary ID |
5R44HD092156-03 |
Status |
Terminated |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
May 5, 2022 |
Est. completion date |
January 18, 2023 |
Study information
Verified date |
January 2023 |
Source |
Baylor College of Medicine |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Each year, females need surgery to create a vaginal canal or pelvic radiation to treat
cancer. The result is often a narrowing or scarring of their vagina. To aid in healing a
stent is often placed. However, current stents are poorly designed. The goal of this trial is
to test newly designed vaginal stents, with the hope of replacing the poorly retained and
uncomfortable standard of care. This trial has two aims. In the first aim, healthy
participants will evaluate two newly designed vaginal stents for retention, comfort, and
safety over 24 hours. The preferred stent will then be worn by the healthy participants for 2
weeks, again evaluating retention, comfort, and safety. In the second aim, the stents will be
evaluated by two different patient populations. Adolescent participants undergoing vaginal
surgery for genetic anomalies, will have a stent placed following surgery for continuous wear
for 2 weeks. Adult participants undergoing vaginal brachytherapy will have the stent placed
following the final brachytherapy treatment. These participants will wear the stent
continuously for 2 weeks, followed by an additional 2 weeks of continuous wear. Each
participant will evaluate the stent for retention, comfort, and safety. We hypothesize the
newly designed stents will be retained longer and be more comfortable compared to current
standards of care.
Description:
After surgery or radiation to the vaginal area, a common patient risk is that their vaginal
tissue sticks together and scars. This can cause the vaginal canal to narrow or shorten. This
can occur in up to 73% of patients and to fix the scarring, more surgery or uncomfortable
procedures may be needed to widen the canal. To prevent the problem of scarring after surgery
or radiation, patients should wear a stent to hold open the vaginal canal. Unfortunately, the
current stents are poorly made and not very advanced. The result can be a poor fit to the
vagina, movement of the stent, and patients not being able to wear the stent for a long
enough time to keep the vaginal tissue from scarring.
The first aim of this trial is for healthy participants to evaluate two newly designed
stents. Each participant will have a stent placed for 24 hours, removed for 24 hours, and the
second stent placed for 24 hours. The participants will evaluate the stent on comfort (during
insertion, wearing, and removal), retention, any impact on daily functions, and chose which
stent performed better overall. That stent will then be placed in the healthy participants
for 2 weeks of continuous wear. Participants will answer daily questionnaires on comfort,
retention, and any adverse effects. Physicians will also be asked to complete questionnaires
at each appointment related to stent performance.
The second aim of the trial is for two different patient populations to evaluate the
preferred stent chosen by the healthy participants. Adolescent girls undergoing vaginal
reconstructive surgery for vaginal anomalies will have a stent placed following surgery.
During the two weeks of continuous wear, participants will be asked to answer daily
questionnaires on comfort, retention, and adverse effects. The stent will be removed at two
weeks, and participants will be asked to complete a follow-up questionnaire at each of their
standard of care appointments, 2, 4, and 6 weeks, 3, 6, and 12 months. Adult females
undergoing vaginal brachytherapy will have a stent placed after their last brachytherapy
treatment. The participants will wear the stent continuously for 2 weeks and be asked to
answer daily questionnaires on comfort, retention, and adverse effects. Participants will
have a 2-week follow-up, during which the stent will be removed, they will be examined, and
the stent will be replaced for 2 more weeks of continuous wear. At the 4-week follow-up, the
stent will be removed and subsequent standard of care follow-ups will continue at 3, 6, and
12 months. Physicians will also be asked to complete questionnaires at each appointment
related to stent performance.
During all phases of the trial, the data safety monitoring board will meet at regularly
scheduled meetings and immediately after any severe or unanticipated adverse event. After our
12 months of follow up, data collected from both participant and physician questionnaires
will be analyzed by the study bio-statistician and compared to retrospective data.